Gilbert Peter, McBain Andrew J
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, United Kingdom.
Clin Microbiol Rev. 2003 Apr;16(2):189-208. doi: 10.1128/CMR.16.2.189-208.2003.
There has recently been much controversy surrounding the increased use of antibacterial substances in a wide range of consumer products and the possibility that, as with antibiotics, indiscriminate use of biocides might contribute to the overall pattern of susceptibility in the general environment and in the clinic. Such speculation, based on the isolation of resistant mutants from in vitro monoculture experiments, is not reflected by an emergence of biocide-resistant strains in vivo. This review provides a broad coverage of the biocide and resistance literature and evaluates the potential risks, perceived from such laboratory monoculture experiments, against evidence gathered over 50 years of field studies. An explanation for the continued effectiveness of broad-spectrum biocidal agents against the decline in efficacy of therapeutic agents is provided based on the fitness costs of resistance and the ubiquity of naturally occurring substances that possess antibacterial effect. While we conclude from this review of the literature that the incorporation of antibacterial agents into a widening sphere of personal products has had little or no impact on the patterns of microbial susceptibility observed in the environment, the associated risks remain finite. The use of such products should therefore be associated with a clear demonstration of added value either to consumer health or to the product life. Hygienic products should therefore be targeted to applications for which the risks have been established.
最近,围绕抗菌物质在各类消费品中的使用增加,以及与抗生素一样,滥用杀生物剂可能会导致总体环境和临床中易感性模式的出现,引发了诸多争议。基于体外单培养实验中抗性突变体的分离得出的此类推测,并未在体内出现抗杀生物剂菌株的情况中得到体现。本综述广泛涵盖了杀生物剂和抗性文献,并根据此类实验室单培养实验所感知到的潜在风险,与50多年来实地研究收集的证据进行了评估。基于抗性的适应性代价以及具有抗菌作用的天然物质的普遍存在,对广谱杀生物剂在治疗剂疗效下降情况下仍持续有效的原因作出了解释。虽然我们从本综述文献中得出结论,将抗菌剂纳入越来越多的个人产品中,对环境中观察到的微生物易感性模式几乎没有影响,但相关风险仍然存在。因此,此类产品的使用应明确证明对消费者健康或产品寿命具有附加价值。卫生产品因此应针对已确定风险的应用。